You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国医疗(08225.HK)弹14%曾高见1.08元 春立/阿里健康/威高/爱康由纪录高续吐近2%-6%
阿思达克 04-24 14:24
中国医疗集团(08225.HK)抗新冠肺炎药迈可欣即将开展海外临床研究,该股今天曾一举重越10天、20天及50天线(0.89元/0.94元/1.04元),一度急弹30%高见1.08元遇压,现造0.94元,急弹14%,一向薄弱成交急增至3,372万股,涉资3,325万元。中国医疗公布,为回应国际抗击新冠肺炎疫情紧急需求,与一家国际CRO公司Pharmadesk签署《迈可欣口服液生物等效性研究协议》。该产品为集团关联制造企业「万全万特制药(厦门)」於今年2月下旬获得独家复产批准的产品(已被中国科学院等研究机构发现对新冠肺炎有抑制作用)。

相反,其余医药相关股普遍受压,且沽压远超大市。蓝筹石药(01093.HK)低见15.08元,现造15.28元,回吐4.1%。药明生物(02269.HK)高开报122.7元欠承接,受制上月盘中所创上市高位123.8元,掉头失守10天线(117.1元),最低见116元,现造116.6元,倒跌4%,旗下药明康德(02359.HK)低见104元,现造105.6元,续吐3.2%。

正探讨发A股可能性的春立医疗(01858.HK)股价由纪录高位连吐第二天,今天反覆续吐5.7%报44.15元即市低位;阿里健康(00241.HK)扭转连续两天破顶强势,股价回吐5.4%,报18.54元。威高股份(01066.HK)及爱康医疗(01789.HK)由纪录高位连吐第二天,现造12.22元及22.65元(均为即市低位),反覆续吐1.9%及2.4%。

复星医药(02196.HK)扭两连涨,股价由52周高位反覆回吐逾1%曾低见29.1元;上海医药(02607.HK)扭四连涨,股价跌2%报13.84元,失守10天线(13.93元)。联邦制药(03933.HK)扭两连涨,股价回吐3.6%报6.96元,失守10天线(7.15元)。不过,昨天高位遇压倒跌的康希诺生物-B(06185.HK)曾回升至149.1元,现造146元,回升2.7%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account